Ayami Morita
Assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Year:
2026
Aim: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been reported to increase hemoglobin levels; however, little is known about the magnitude of their anemia‐improving effect in patients with advanced chronic kidney disease. We aimed to determine the influence of albuminuria and renal dysfunction on the anemia‐improving effects of SGLT2 inhibitors in patients with Type 2 diabetes (T2D). Materials and Methods: In this clinically based retrospective longitudinal study, the records of 4664 consecutive patients with T2D were reviewed. We investigated the effects of albuminuria and eGFR at baseline on change in hemoglobin after 3 months of SGLT2 inhibitor treatment by a multivariable linear regression analysis with calculation of the unstandardized partial regression coefficient ( B ). Results: Among the patients with T2D, 230 patients (male, n = 170; female, n = 60; age, 67.0 ± 11.5 years) were eligible for the analysis. Patients with macroalbuminuria (urine albumin‐to‐creatinine ratio (uACR) > 300 mg/g or urine protein‐to‐creatinine ratio (uPCR) > 500 mg/g) exhibited a significantly smaller increase in hemoglobin after the initiation of SGLT2 inhibitor treatment ( B −5.923 g/L, p = 0.003) compared to patients with normoalbuminuria (uACR 3500 mg/g, did not experience increased hemoglobin from SGLT2 inhibitor treatment. However, we could not find a significant association between the eGFR at baseline (including eGFR ≤ 15 mL/min/1.73 m 2 ) and change in hemoglobin with SGLT2 inhibitor treatment. Conclusions: Our findings indicate that severely increased albuminuria attenuates the anemia‐improving effect of SGLT2 inhibitors for at least 3 months after their administration.
Year:
2025
Selective serotonin reuptake inhibitors (SSRIs) are widely used in depression treatment. However, the relationship between treatment efficacy and plasma concentrations remains unclear. We assessed whether the anti‐depressive response can be predicted based on the pharmacokinetic (PK) data of paroxetine, a frequently used SSRI. During treatment, we measured the plasma paroxetine concentrations in 179 paroxetine‐treated patients with major depressive disorder. Of these patients, 50 patients had received a pre‐treatment personality assessment using the Temperament and Character Inventory at baseline, and their depression severity was assessed using the Montgomery‐Asberg Depression Rating Scale (MADRS) at baseline and 1, 2, 4, and 6 weeks after treatment initiation. We conducted population PK modeling followed by a population PK‐pharmacodynamic (popPK/PD) model to analyze the enhancement in depression severity until 6 weeks of paroxetine treatment using nonlinear mixed‐effects modeling. Additionally, we developed machine learning models to predict the likelihood of remission after 6 weeks. The contribution of each feature to the prediction was explained using SHapley Additive exPlanations (SHAP) values. The area under the plasma paroxetine concentration‐time curve during the first week (AUC 0–1week ) and MADRS score after 1 week of treatment (MADRS W1 ) were incorporated into the popPK/PD model. The SHAP values indicated that the AUC 0–1week and MADRS W1 were the significant predictors of remission. Our results indicate that therapeutic responsiveness to paroxetine can be anticipated from its cumulative exposure, highlighting the clinical relevance of assessing SSRI blood concentrations.
Year:
2025
Collaborators (3)
Norio Yasui‐Furukori
Associate Professor
Dokkyo Medical University
Kentaro Oniki
Kumamoto University
Junji Saruwatari
Professor
Kumamoto University
Make your next move.
Prepare your application
Review drafts before you send them.